Predictive Technology Group, Inc. (Pred) Appoints Ronald Barhorst To Chair Its Finanical Advisory Board
In January 2013, after 25 years in the financial services industry, Mr. Barhorst retired as President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies. Mr. Barhorst currently serves as Chairman of the California State University Foundation Board of Governors, a position he has held for the past 15 years.
“I have had the opportunity to work with Predictive Technology Group or their predecessor companies for the past 8 years,” said Ronald Barhorst. “I am impressed with the brilliant minds that drive this Company and the substantial impact that this Company represents in targeted gene based therapeutics and women’s health.”
“As we move forward to becoming a full-reporting company under the Securities Exchange Act of 1934, Ron’s wealth of experience, gained in senior executive roles in the financial industry, will help ensure PRED maintains proper governance, oversight and guidance through its Board and Committees,” said Bradley Robinson, CEO of Predictive Technology Group.
Predictive Therapeutics plans to launch several new molecular diagnostic tests focused on women’s health, and a therapeutic drug for the potential treatment of endometriosis.
About Predictive Technology Group, Inc.
Predictive Technology Group, Inc. (OTC PINK: PRED), a Salt Lake City, UT, based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively, www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.
For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and email@example.com.
Forward-Looking Statements- To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.